Printer Friendly

BIOMIRA INC. ANNOUNCES RESULTS OF PHASE I CLINICAL TRIALS OF ITS THERATOPE PRODUCTS

 BIOMIRA INC. ANNOUNCES RESULTS OF PHASE I CLINICAL TRIALS
 OF ITS THERATOPE PRODUCTS
 EDMONTON, Alberta, July 23 /PRNewswire/ -- Biomira Inc. (Toronto, Montreal, Calgary: BRA) has released results of the Phase I clinical trials of its THERATOPE(R) products for treatment of cancers of the ovary and breast. The tests, which began in 1990, were concluded recently. The results were presented by Dr. Michael Longenecker, developer of the therapeutic injectable, to approximately 200 attendees at the annual meeting of the American Association of Clinical Chemists held in Chicago, July 19 to 23.
 In compliance with regulatory guidelines, up to 12 volunteer patients are in Phase I clinical trials to determine the safety of a new drug -- that is, to determine whether the drug causes little or no toxic reaction at a dosage level expected to be employed in treatment. These tests were conducted at a cancer institute in Canada following acceptance of Biomira's investigational new drug (IND) submission to the Canada Health Protection Branch (HPB).
 The results of the two Phase I clinical trials indicate no serious adverse clinical reactions to Biomira's cancer vaccine. On the basis of these trials, Biomira has filed three additional IND's with the HPB for Phase II trials, which will test for safety and efficacy in breast, pancreatic and colon cancer.
 Longenecker reported that in the first study patients selected were those whose widespread ovarian cancer had not responded to chemotherapy. The patients were injected with THERATOPE(R) plus DETOX(R) adjuvant over a 20-week period. Longenecker explained to the meeting that the treatment was found to be safe and to cause only mild adverse effects, such as redness, swelling and, in some patients, modern ulceration of the skin, at the site of injection. Half of the patients are alive and active an average of over 80 weeks since entering the study while the non-survivors lived an average of 30 weeks following the commencement of treatment.
 In the second study, 12 patients with measurable breast cancer, two with widespread disease and 10 with minimal metastasis or spread of the disease were entered in the program. Again, the treatment was found to be safe and to cause adverse effects similar to those seen in the ovarian cancer patients. Three patients, including the two with widespread malignancy, showed progression of disease, and five were classified as having stable disease. Two patients were classified as showing a "mixed response" which is defined as some of the tumors getting smaller while others increased or did not change in size. "Partial response" was determined in the other two patients whose tumor mass measured 50 percent or less in size than that which was recorded at the start of the breast cancer study.
 Biomira is encouraged by the results of both studies. Having treated 24 patients with our THERATOPE(R) formulation we believe the Phase I studies show that the product is safe and stimulates their immune systems to respond against the cancer antigen.
 Biomira's Active Specific Immunotherapy (ASI) activity is centered on the development of specific THERATOPE(R) products to treat a variety of common cancers. The drug is administered like a conventional vaccine, although it is not a vaccine in the traditional sense. It is not given to prevent cancer, but to treat the disease. The patient is injected under the skin with a small gauge needle. Utilizing Biomira's proprietary, synthetic, cancer associated antigens, THERATOPE(R) is designed to stimulate the patient's own immune system to target and reject cancer cells. The procedure is conducted on an out-patient basis.
 Biomira is proceeding to Phase II clinical trials, still involving a limited number of volunteer patients, to determine efficacy of the drug, dosage, side effects and safety at additional test sites in North America and Europe.
 Biomira is a Canadian biotechnology company developing technology and products to diagnose and treat cancer, and is using its technology in three areas: Active Specific Immunotherapy; radioimmunoimaging and radioimmunotherapy; and in vitro cancer diagnostics. Biomira holds significant interests in H.C.S. Health Care Systems Inc. of Vancouver, and ADI Diagnostics Inc. of Toronto.
 -0- 7/23/92
 /CONTACT: Alex McPherson, M.D., Ph.D., president and CEO, or Michael Longenecker, Ph.D., senior VP and COO, of Immunotherapeutics Division; Jane Jack, (investors), 403-490-2812/
 (BRA.) CO: Biomira Inc. ST: Alberta IN: MTC SU:


JL -- LA038 -- 2760 07/23/92 17:10 EDT
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Jul 23, 1992
Words:727
Previous Article:GOLDEN POULTRY BOARD DECLARES REGULAR QUARTERLY CASH DIVIDEND
Next Article:CHRYSLER REPORTS ASSEMBLY PLANT SCHEDULE FOR WEEK ENDING JULY 31
Topics:


Related Articles
BIOMIRA INC. DISCUSSES PRELIMINARY OBSERVATIONS IN PHASE II CLINICAL TRIALS USING THERATOPE(R) STnKLH AT SCIENTIFIC PRESENTATION
BIOMIRA INC. ANNOUNCES START OF U.S. PHASE II BREAST CANCER CLINICAL TRIAL USING THERATOPE(R) STnKLH
RIBI CANCER VACCINE ADJUVANT TECHNOLOGY REFERENCED IN FOUR PRESENTATIONS AT CANCER IMMUNOTHERAPY MEETING
ATTENTION BUSINESS EDITORS:
Biomira Focuses on Therapeutic Vaccines
Biomira Commences Clinical Trial With MUC-1 Cancer Vaccine
Biomira's Bridging Study Fully Enrolled to Test Theratope(R) Cancer Vaccine
Biomira's Bridging Study Fully Enrolled to Test Theratope(R) Cancer Vaccine
Biomira Presents Update On Recent Activities At Yorkton Conference.
Nancy J. Wysenski Joins Biomira's Board Of Directors.

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters